Atox ‘Remains On Track’ Despite ACCUTE Setback
CEO Says Reltecimod NDA In NTSI Set For September
After talking with the FDA, Atox will file an NDA for its necrotizing soft tissue infections therapy despite missing primary endpoints in a pivotal trial, the biotech’s CEO tells Scrip.
